46.9 F
Elizabeth City
Friday, May 14, 2021
type here...
Uncategorized

Practice-Changing Trial in Metastatic Papillary RCC

By editor
0
25
Practice-Changing Trial in Metastatic Papillary RCC

Must read

editorhttps://salvanews.com

(MedPage Today) — Cabozantinib (Cabometyx) came out on top as upfront therapy in metastatic papillary renal cell carcinoma (RCC) in a randomized phase II study.
Treatment with the multikinase inhibitor yielded a median progression-free survival…
Read More

Previous articleNew Standard in High-Risk Muscle-Invasive Bladder Cancer?
Next articleA CLEAR Upfront Winner in Advanced RCC?
- Advertisement -

More articles

Uncategorized

Exercise Helps the Heart, But Can Manual Labor Hurt?

editor - 0
Physical activity is essential to maintain and improve health, but some research has suggested that physical activity required at work may not provide the same benefits and may even increase heart risk.
Read more
Uncategorized

CDC: Vaccinated? You Don’t Need a Mask Indoors

editor - 0
People who are fully vaccinated against COVID-19 are no longer required to wear masks or physically distance, regardless of location or size of the gathering, the CDC announced today.
Read more
Uncategorized

Coronavirus Lingers in Penis and Could Cause Impotence

editor - 0
Coronavirus infection is already known to damage blood vessels, and vessels that supply blood to the penis appear to be no exception.
Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article

© Salvanews. All rights reserved.

About Us

Popular Category

Editor Picks